If you’ve already registered, please click here to log in to the webcast.

The clinical significance of the tumor immune microenvironment is well established – in particular, the role of tumor-infiltrating lymphocytes (TILs), which can act as predictive and prognostic biomarkers in a range of solid tumors.

Spatial omics techniques such as multiplex immunofluorescence, fluorescence in situ hybridization, and imaging mass cytometry have added to knowledge about how the spatial architecture of many solid cancers and their microenvironments can impact clinical prognosis and response to treatments. However, the feasibility of applying such analysis in routine clinical diagnosis remains a challenge.

This webcast will describe discoveries made using spatial omics in breast cancer and metastasis to the brain, the application of such analyses on retrospective cohorts to predict patient outcomes, and some of the challenges that arise in applying these technologies to clinical practice, such as in routine biopsies.

• Complexity of the tumor immune system, not limited to T cells and macrophages
• How spatial characterization of the tumor immune landscape of cancer is predictive of patient outcome.
• How we can use spatial-omics technologies to predict patient response to therapy and outcomes